$3.80 Million in Sales Expected for Sol-Gel Technologies Ltd. (NASDAQ:SLGL) This Quarter

Equities analysts expect that Sol-Gel Technologies Ltd. (NASDAQ:SLGLGet Rating) will announce $3.80 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Sol-Gel Technologies’ earnings, with the highest sales estimate coming in at $5.00 million and the lowest estimate coming in at $2.60 million. Sol-Gel Technologies posted sales of $700,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 442.9%. The firm is scheduled to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Sol-Gel Technologies will report full-year sales of $23.69 million for the current fiscal year, with estimates ranging from $16.00 million to $31.41 million. For the next fiscal year, analysts anticipate that the business will report sales of $31.81 million, with estimates ranging from $25.20 million to $38.41 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Sol-Gel Technologies.

Sol-Gel Technologies (NASDAQ:SLGLGet Rating) last posted its quarterly earnings results on Wednesday, March 30th. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.40 by $0.21. Sol-Gel Technologies had a return on equity of 7.03% and a net margin of 10.30%.

Several research firms have recently commented on SLGL. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Sol-Gel Technologies in a research report on Monday. Zacks Investment Research upgraded Sol-Gel Technologies from a “hold” rating to a “buy” rating and set a $8.00 target price for the company in a report on Wednesday, April 6th. Finally, Raymond James decreased their price target on Sol-Gel Technologies from $21.00 to $17.00 and set a “strong-buy” rating for the company in a report on Friday, April 1st.

SLGL stock opened at $7.19 on Tuesday. The business has a fifty day moving average of $7.35 and a two-hundred day moving average of $7.81. The stock has a market cap of $146.60 million, a price-to-earnings ratio of 55.31 and a beta of 1.17. Sol-Gel Technologies has a 52-week low of $6.12 and a 52-week high of $15.31.

Hedge funds have recently modified their holdings of the stock. We Are One Seven LLC acquired a new position in Sol-Gel Technologies in the 4th quarter valued at about $74,000. Susquehanna International Group LLP boosted its stake in shares of Sol-Gel Technologies by 34.0% during the 4th quarter. Susquehanna International Group LLP now owns 16,862 shares of the company’s stock worth $125,000 after acquiring an additional 4,275 shares in the last quarter. Raymond James & Associates boosted its stake in shares of Sol-Gel Technologies by 14.1% during the 3rd quarter. Raymond James & Associates now owns 36,608 shares of the company’s stock worth $365,000 after acquiring an additional 4,519 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. boosted its stake in shares of Sol-Gel Technologies by 6.2% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 129,011 shares of the company’s stock worth $1,288,000 after acquiring an additional 7,544 shares in the last quarter. Hedge funds and other institutional investors own 28.79% of the company’s stock.

Sol-Gel Technologies Company Profile (Get Rating)

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions.

Read More

Get a free copy of the Zacks research report on Sol-Gel Technologies (SLGL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sol-Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol-Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.